Alnylam Pharma ( ($ALNY) ) has issued an update. On September 30, 2025, Alnylam Pharmaceuticals entered into a Credit Agreement with Bank of ...

Dr. Jeanne Marrazzo had filed a whistleblower complaint against the administration for actions she said had jeopardized research subjects, defied court orders, and undermined vaccine research, The New ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) ranks among the best biotech stocks to buy. RBC Capital maintained its Outperform rating for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on September 19 and ...

Alnylam Pharmaceuticals ( NASDAQ: ALNY) has pulled a television ad for its drug Amvuttra (vutrisiran) after the U.S. FDA determined the spot was misleading. Amvuttra is approved for two heart ...

The company was one of many to get letters last month from the US Food and Drug Administration calling out what the agency ...

Investigators are assessing whether treatment with the angiotensinogen-targeting RNAi agent reduces patients' risk of cardiovascular disease.

George Tidmarsh, head of the FDA’s Center for Drug Evaluation and Research, wrote that the ad incorrectly suggested patients "can be carefree" about their heart condition and "misleadingly suggests ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the most promising biotech stocks to buy according to hedge funds.

Alnylam joins Illumina and NashBio’s Alliance for Genomic Discovery to expand its 250,000 genome dataset and fuel RNAi research.

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ ...

Detailed price information for Aurinia Pharm Ord (AUPH-Q) from The Globe and Mail including charting and trades.

Dublin-based Aerska launched on Wednesday with $21 million in seed funding and a technology designed to shuttle RNA ...